SK Group's investment holding company, SK, will acquire a US gene and cell therapy (GTC) company.
SK said on the 16th that it is in exclusive negotiations to acquire The Center for Breakthrough Medicines (CBM), a U.S. consignment production (CMO) company specializing in gene and cell treatment.
The amount of investment has not been disclosed, but the market expects it to reach hundreds of billions of won.
SK plans to finalize the contract with CBM within this year. It is a large investment in eight months after acquiring French gene and cell therapy CMO company 'Yposkesi' in March.
SK plans to become the world's top five CMO with sales of 2 trillion won based on bio-innovative new drugs such as synthetic drugs and gene and cell treatments.
In particular, through this investment, it is expected to establish itself as an CMO specializing in gene and cell therapy in the United States and Europe, the world's largest pharmaceutical market.
Reporter Lee Ji-sun stockmk2020@gmail.com
